Review
Update of literature from cystic fibrosis registries 2012–2015. Part 6: Epidemiology, nutrition and complications
Donatello Salvatore MD,
Roberto Buzzetti MD,
Gianni Mastella MD,
Corresponding Author
Donatello Salvatore MD
Cystic Fibrosis Center, AOR Hospital San Carlo, Via Potito Petrone, Potenza, 85100 Italy
Correspondence to: Donatello Salvatore, MD, Cystic Fibrosis Center, AOR Hospital San Carlo, Via Potito Petrone, Potenza 85100, Italy. E-mail: [email protected]
Search for more papers by this authorRoberto Buzzetti MD
Italian Cystic Fibrosis Research Foundation, Ospedale Maggiore, Verona, Italy
Search for more papers by this authorGianni Mastella MD
Italian Cystic Fibrosis Research Foundation, Ospedale Maggiore, Verona, Italy
Search for more papers by this authorDonatello Salvatore MD,
Roberto Buzzetti MD,
Gianni Mastella MD,
Corresponding Author
Donatello Salvatore MD
Cystic Fibrosis Center, AOR Hospital San Carlo, Via Potito Petrone, Potenza, 85100 Italy
Correspondence to: Donatello Salvatore, MD, Cystic Fibrosis Center, AOR Hospital San Carlo, Via Potito Petrone, Potenza 85100, Italy. E-mail: [email protected]
Search for more papers by this authorRoberto Buzzetti MD
Italian Cystic Fibrosis Research Foundation, Ospedale Maggiore, Verona, Italy
Search for more papers by this authorGianni Mastella MD
Italian Cystic Fibrosis Research Foundation, Ospedale Maggiore, Verona, Italy
Search for more papers by this authorConflict of interest: None.
Summary
Patient registries provide useful information to afford more knowledge on rare diseases like Cystic Fibrosis (CF). Twenty-two studies originating from national CF registries, focusing on demographics, survival, genetics, nutritional status, and non-pulmonary complications, were published between December 2011 and March 2015. The purpose of this review article is to examine these reports, aiming attention to the clinical characteristics of CF patients included in the registries, current, and estimated future epidemiological data, the role of gender gap, the increasing survival in different countries. Some studies offer insights into pubertal growth and non-pulmonary complications, such as liver disease, nephropathy, and cancer. Pediatr Pulmonol. 2017;52:390–398. © 2016 Wiley Periodicals, Inc.
REFERENCES
- 1 R Gliklich, N Dreyer, M Leavy, editors. Registries for evaluating patient outcomes: a user's guide, 3rd edition. Two volumes. (Prepared by the Outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under Contract No. 290 2005 00351 TO7.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality; 2014. http://www.effectivehealthcare.ahrq.gov/registries-guide-3.cfm
- 2 Buzzetti R, Salvatore D, Baldo E, Forneris MP, Lucidi V, Manunza D, Marinelli I, Messore B, Neri AS, Raia V, et al. An overview of international literature from cystic fibrosis registries: 1. Mortality and survival studies in cystic fibrosis. J Cyst Fibros 2009; 8: 229–237.
- 3 Salvatore D, Buzzetti R, Baldo E, Forneris MP, Lucidi V, Manunza D, Marinelli I, Messore B, Neri AS, Raia V, et al. An overview of international literature from cystic fibrosis registries 2. Neonatal screening and nutrition/growth. J Cyst Fibros 2010; 9: 75–83.
- 4 Salvatore D, Buzzetti R, Baldo E, Forneris MP, Lucidi V, Manunza D, Marinelli I, Messore B, Neri AS, Raia V, et al. An overview of international literature from cystic fibrosis registries part 3. Disease incidence, genotype/phenotype correlation, microbiology, pregnancy, clinical complications, lung transplantation, and miscellanea. J Cyst Fibros 2011; 10: 71–85.
- 5 Salvatore D, Buzzetti R, Baldo E, Furnari ML, Lucidi V, Manunza D, Marinelli I, Messore B, Neri AS, Raia V, et al. An overview of international literature from cystic fibrosis registries. Part 4: update 2011. J Cyst Fibros 2012; 11: 480–493.
- 6 Salvatore D, Buzzetti R, Mastella G. An overview of international literature from cystic fibrosis registries. Part 5: update 2012–2015 on lung disease. Pediatr Pulmonol 2016; DOI: 10.1002/ppul.23473. [Epub ahead of print].
- 7 Thomas M, Lemonnier L, Gulmans V, Naehrlich L, Vermeulen F, Cuppens H, Castellani C, Norek A, De Boeck K. Is there evidence for correct diagnosis in cystic fibrosis registries? J Cyst Fibros 2014; 13: 275–280.
- 8 Viviani L, Zolin A, Mehta A, Olesen HV. The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry. Orphanet J Rare Dis 2014; 9: 81.
- 9 Fogarty AW, Britton J, Clayton A, Smyth AR. Are measures of body habitus associated with mortality in cystic fibrosis? Chest 2012; 142: 712–717.
- 10 McCarthy C, Dimitrov BD, Meurling IJ, Gunaratnam C, McElvaney NG. The CF-ABLE score: a novel clinical prediction rule for prognosis in patients with cystic fibrosis. Chest 2013; 143: 1358–1364.
- 11 Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153: 345–352.
- 12 Buzzetti R, Alicandro G, Minicucci L, Notarnicola S, Furnari ML, Giordano G, Lucidi V, Montemitro E, Raia V, Magazzù G, et al. Validation of a predictive survival model in Italian patients with cystic fibrosis. J Cyst Fibros 2012; 11: 24–29.
- 13 MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH, Marshall BC. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the cystic fibrosis foundation patient registry. Ann Intern Med 2014; 161: 233–241.
- 14 Hoo ZH, Wildman MJ, Teare MD. Exploration of the impact of ‘mild phenotypes’ on median age at death in the U.K. CF registry. Respir Med 2014; 108: 716–721.
- 15 Stephenson AL, Tom M, Berthiaume Y, Singer LG, Aaron SD, Whitmore GA, Stanojevic S. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. Eur Respir J 2015; 45: 670–679.
- 16 Aaron SD, Stephenson AL, Cameron DW, Whitmore GA. A statistical model to predict one-year risk of death in patients with cystic fibrosis. J Clin Epidemiol 2015; 68: 1336–1345.
- 17 McKone EF, Velentgas P, Swenson AJ, Goss CH. Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype. J Cyst Fibros 2015; 14: 580–586.
- 18 Rowe SM, Accurso F, Clancy JP. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc 2007; 4: 387–398.
- 19 Burgel PR, Bellis G, Olesen HV, Viviani L, Zolin A, Blasi F, Elborn JS. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J 2015; 46: 133–141.
- 20 Elborn JS, Bell SC, Madge SL, Burgel PR, Castellani C, Conway S, De Rijcke K, Dembski B, Drevinek P, Heijerman HG, et al. Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. Eur Respir J 2016; 47: 420–428.
- 21 Hurley MN, McKeever TM, Prayle AP, Fogarty AW, Smyth AR. Rate of improvement of CF life expectancy exceeds that of general population-observational death registration study. J Cyst Fibros 2014; 13: 410–415.
- 22 Alicandro G, Frova L, Di Fraia G, Colombo C. Cystic fibrosis mortality trend in Italy from 1970 to 2011. J Cyst Fibros 2015; 14: 267–274.
- 23 Chotirmall SH, Smith SG, Gunaratnam C, Cosgrove S, Dimitrov BD, O'Neill SJ, Harvey BJ, Greene CM, McElvaney NG. Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N Engl J Med 2012; 366: 1978–1986.
- 24 De Boeck K, Zolin A, Cuppens H, Olesen HV, Viviani L. The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibros 2014; 13: 403–409.
- 25 Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008; 108: 832–839.
- 26 Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, Kashirskaya N, Munck A, Ratjen F, Schwarzenberg SJ, et al. European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros 2014; 13: S23–S42.
- 27 Lahiri T, Hempstead SE, Brady C, Cannon CL, Clark K, Condren ME, Guill MF, Guillerman RP, Leone CG, Maguiness K, et al. Clinical practice guidelines from the cystic fibrosis foundation for preschoolers with cystic fibrosis. Pediatrics 2016; 137: e20151784.
- 28 Bradley GM, Blackman SM, Watson CP, Doshi VK, Cutting GR. Genetic modifiers of nutritional status in cystic fibrosis. Am J Clin Nutr 2012; 96: 1299–1308.
- 29 Haupt ME, Kwasny MJ, Schechter MS, McColley SA. Pancreatic enzyme replacement therapy dosing and nutritional outcomes in children with cystic fibrosis. J Pediatr 2014; 164: 1110–1115.
- 30 Bournez M, Bellis G, Huet F. Growth during puberty in cystic fibrosis: a retrospective evaluation of a French cohort. Arch Dis Child 2012; 97: 714–720.
- 31 Yen EH, Quinton H, Borowitz D. Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. J Pediatr 2013; 162: 530–535.
- 32 Zhang Z, Lindstrom MJ, Lai HJ. Pubertal height velocity and associations with prepubertal and adult heights in cystic fibrosis. J Pediatr 2013; 163: 376–382.
- 33 Heltshe SL, Borowitz DS, Leung DH, Ramsey B, Mayer-Hamblett N. Early attained weight and length predict growth faltering better than velocity measures in infants with CF. J Cyst Fibros 2014; 13: 723–729.
- 34 Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, Spear SL, Michel SH, Parad RB, White TB, Farrell PM, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009; 155: S73–S93.
- 35 Machogu E, Cao Y, Miller T, Simpson P, Levy H, Quintero D, Goday PS. Comparison of WHO and CDC growth charts in predicting pulmonary outcomes in cystic fibrosis. J Pediatr Gastroenterol Nutr 2015; 60: 378–383.
- 36 Quon BS, Mayer-Hamblett N, Aitken ML, Goss CH. Risk of post-lung transplant renal dysfunction in adults with cystic fibrosis. Chest 2012; 142: 185–191.
- 37 Somerville R, Lackson A, Zhou S, Fletcher C, Fitzpatrick P. Non-pulmonary chronic diseases in adults with cystic fibrosis: analysis of data from the Cystic Fibrosis Registry. Ir Med J 2013; 106: 166–168.
- 38 Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst 2013; 105: 122–129.
- 39 Stankovic Stojanovic K, Hubert D, Leroy S, Dominique S, Grenet D, Colombat M, Clement A, Fayon M, Grateau G. Cystic fibrosis and AA amyloidosis: a survey in the French cystic fibrosis network. Amyloid 2014; 21: 231–237.
- 40 Wagener JS, Woo MS, Pasta DJ, Konstan MW, Morgan WJ. Liver involvement in the Hispanic population of North America with cystic fibrosis. J Pediatr Gastroenterol Nutr 2014; 59: 476–479.
- 41 Mehta A. The how (and why) of disease registers. Early Hum Dev 2010; 86: 723–728.
- 42 Knapp EA, Fink AK, Goss CH, Sewall A, Ostrenga J, Dowd C, Elbert A, Petren KM, Marshall BC. The cystic fibrosis foundation patient registry: design and methods of a national observational disease registry. Ann Am Thorac Soc 2016; 13: 1173–1179.
Citing Literature
